HALO Stock: Price, Earnings History and SEC Filings
Halozyme Therapeutics, Inc. (HALO) last traded at $130.91, down 0.21% on the latest session and up 18.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $2.17 against an analyst estimate of $1.73, a beat of 25.4%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
HALO earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $2.17 | $1.73 | +25.43% |
| Mar 2026 | May 11, 2026 | $1.48 | $1.46 | +1.37% |
| Dec 2025 | Feb 17, 2026 | $-0.35 | $2.07 | -116.91% |
| Sep 2025 | Nov 3, 2025 | $1.63 | $1.54 | +5.84% |
HALO beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How HALO reacts to earnings
Across its last 8 earnings releases, HALO moved 7.9% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | +20.24% |
| 2026-05-11 | After close | +6.81% |
| 2026-02-17 | After close | -9.01% |
| 2026-01-28 | Before open | +3.72% |
| 2025-11-03 | After close | +2.79% |
| 2025-08-05 | After close | +2.48% |
| 2025-05-06 | After close | +18.12% |
| 2025-02-18 | After close | -0.22% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
HALO financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $1.4B | $317M | $645M | 22.7% | $2.56 |
| 2024 | $1.0B | $444M | $468M | 43.7% | $3.43 |
| 2023 | $829M | $282M | $373M | 34.0% | $2.10 |
| 2022 | $660M | $202M | $235M | 30.6% | $1.44 |
| 2021 | $443M | $403M | $298M | 90.8% | $2.74 |
| 2020 | $268M | $129M | $53M | 48.2% | $0.91 |
| 2019 | $196M | -$72M | -$89M | -36.9% | $-0.50 |
| 2018 | $152M | -$80M | -$54M | -52.9% | $-0.56 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for HALO
- 8-K · Sep 30, 2026Officer or director change
- 8-K · Sep 22, 2026Material agreement, New financial obligation, Unregistered share sale
- 8-K · Sep 18, 2026Other events, Financial statements and exhibits
- 8-K · Sep 16, 2026Other events, Financial statements and exhibits
- 8-K · Aug 18, 2026Officer or director change
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 2, 2026Officer or director change
- 10-Q · May 11, 2026
- 8-K · May 11, 2026Results of operations, Financial statements and exhibits
Insider filing activity
HALO insiders filed 8 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
HALO news
- Halozyme Therapeutics IncOct 30, 2026 · 247wallst.com
- HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Oct 30, 2026 · finance.yahoo.com
- Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?Oct 29, 2026 · finance.yahoo.com
- Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- What Did Halozyme Stock Investors Miss Before The Run?Oct 28, 2026 · trefis.com
- Strong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth MomentumOct 27, 2026 · finance.yahoo.com
- TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataOct 26, 2026 · finance.yahoo.com
- Incyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyOct 26, 2026 · finance.yahoo.com
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.